The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Open accessAbstract
STUDY OBJECTIVES: To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD. DESIGN: A stratified, randomized, double-blind, double-dummy, placebo-controlled, parallel group clinical trial. SETTING: Multiple sites at clinics and university medical centers throughout the United States. PATIENTS: Four hundred eleven symptomatic patients with COPD with FEV1 < or = 65% predicted and no clinically significant concurrent disease. INTERVENTIONS: Comparison of inhaled salmeterol (42 microg twice daily), inhaled ipratropium bromide (36 microg four times a day), and inhaled placebo (2 puffs four times a day) over 12 weeks. RESULTS: Salmeterol xinafoate was significantly (p < 0.0001) better than placebo and ipratropium in improving lung function at the recommended doses over the 12-week trial. Both salmeterol and ipratropium reduced dyspnea related to activities of daily living compared with placebo; this improvement was associated with reduced use of supplemental albuterol. Analyses of time to first COPD exacerbation revealed salmeterol to be superior to placebo and ipratropium (p < 0.05). Adverse effects were similar among the three treatments. CONCLUSIONS: These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychophysical bases of perceived exertion
BORG, G. A. V. (1982) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198205000-00012 · Cited by 16,580
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
A measure of quality of life for clinical trials in chronic lung disease
Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987) · Thorax · doi:10.1136/thx.42.10.773 · Cited by 1,721
Reference spirometric values using techniques and equipment that meet ATS recommendations.
Terrin, M. (1981) · PubMed · doi:10.1164/arrd.1981.124.6.763c · Cited by 1,374
Anthonisen, N. R. (1994) · JAMA · doi:10.1001/jama.1994.03520190043033 · Cited by 1,341
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Self-citationManagement of Chronic Obstructive Pulmonary Disease
Sutherland, E. R., & Cherniack, R. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030415 · Cited by 563
Killian, K. J., Leblanc, P., Martin, D. H., Summers, E., Jones, N. L., & Campbell, E. J. M. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/146.4.935 · Cited by 544
O'Donnell, D. E., & Webb, K. A. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.5.1351 · Cited by 543
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
“Regular use of a longacting b2-agonist (107) or a short- or long-acting anticholinergic improves health status (106–108).”
BackgroundCOPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430407 · Cited by 1,078
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Casaburi, R., Mahler, D. A., Jones, P. W., Wanner, A., San Pedro, G., ZuWallack, R. L., Menjoge, S. S., Serby, C. W., & Witek, T. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00269802 · Cited by 881
Self-citationEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
O'Donnell, D. E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Make, B., & Magnussen, H. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00116004 · Cited by 859
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationWedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., & Stockley, R. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-973oc · Cited by 827
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Vincken, W., van Noord, J. A., Greefhorst, A. P. M., Bantje, T. A., Kesten, S., Korducki, L., & Cornelissen, P. J. G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00238702 · Cited by 736
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
COPD exacerbations: definitions and classifications
Burge, S., & Wedzicha, J. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00078002 · Cited by 664
Aaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00152 · Cited by 649
Pauwels, R., Buist, A. S., Calverley, P., Jenkins, C. R., Hurd, S. S., & Lenfant, C. J. M. (2001) · Respiratory Care · doi:10.1177/002013240104600806 · Cited by 615
Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
Kim, V., & Criner, G. J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1843ci · Cited by 513
Mahler, D. A., Wire, P., Horstman, D., Chang, C.-N., Yates, J., Fischer, T., & Shah, T. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2112055 · Cited by 495
Self-citationDonohue, J. F., van Noord, J. A., Bateman, E. D., Langley, S. J., Lee, A., Witek, T. J., Kesten, S., & Towse, L. (2002) · Chest · doi:10.1378/chest.122.1.47 · Cited by 471
Self-citationExacerbations of chronic obstructive pulmonary disease
Celli, B. R., & Barnes, P. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00109906 · Cited by 462
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Siva, R., Green, R. H., Brightling, C. E., Shelley, M., Hargadon, B., McKenna, S., Monteiro, W., Berry, M., Parker, D., Wardlaw, A. J., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00146306 · Cited by 453
Brusasco, V (2005) · Thorax · doi:10.1136/thx.2005.brusascolett · Cited by 431
Brusasco, V (2003) · Thorax · doi:10.1136/thorax.58.5.399 · Cited by 409
Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
Sin, D. D., McAlister, F. A., Man, S. F. P., & Anthonisen, N. R. (2003) · JAMA · doi:10.1001/jama.290.17.2301 · Cited by 404
O'Donnell, D. E., Voduc, N., Fitzpatrick, M., & Webb, K. A. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00072703 · Cited by 365
Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease
DAHL, R., GREEFHORST, L. A. P. M., NOWAK, D., NONIKOV, V., BYRNE, A. M., THOMSON, M. H., TILL, D., & DELLA CIOPPA, G. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.5.2007006 · Cited by 358
Impact of exacerbations on COPD
Anzueto, A. (2010) · European Respiratory Review · doi:10.1183/09059180.00002610 · Cited by 353
(2004) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-120030163 · Cited by 351
van Noord, J. A., Aumann, J.-L., Janssens, E., Smeets, J. J., Verhaert, J., Disse, B., Mueller, A., & Cornelissen, P. J. G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00140404 · Cited by 341
Hanania, N. A., Darken, P., Horstman, D., Reisner, C., Lee, B., Davis, S., & Shah, T. (2003) · Chest · doi:10.1378/chest.124.3.834 · Cited by 327
Herland, K., Akselsen, J.-P., Skjønsberg, O. H., & Bjermer, L. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.03.026 · Cited by 323
Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-244oc · Cited by 314
Prevention of Acute Exacerbations of COPD
Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., et al. (2015) · Chest · doi:10.1378/chest.14-1676 · Cited by 288
The impact of reducing dose frequency on health outcomes
Richter, A., Anton, S. E., Koch, P., & Dennett, S. L. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80222-9 · Cited by 271
Exacerbations of Chronic Obstructive Pulmonary Disease
(2016) · Respiratory Infections · doi:10.3109/9781420080353-7 · Cited by 270
RENNARD, S. I., ANDERSON, W., ZuWALLACK, R., BROUGHTON, J., BAILEY, W., FRIEDMAN, M., WISNIEWSKI, M., & RICKARD, K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.9903053 · Cited by 265
Self-citationNannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Saey, D., Debigaré, R., LeBlanc, P., Mador, M. J., Côté, C. H., Jobin, J., & Maltais, F. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-856oc · Cited by 260
Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD
ZuWallack, R. L., Mahler, D. A., Reilly, D., Church, N., Emmett, A., Rickard, K., & Knobil, K. (2001) · Chest · doi:10.1378/chest.119.6.1661 · Cited by 258
Self-citationExacerbation rate, health status and mortality in COPD – a review of potential interventions
Seemungal, T. (2009) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3385 · Cited by 197
A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD
Liesker, J. J. W., Wijkstra, P. J., Ten Hacken, N. H. T., Koëter, G. H., Postma, D. S., & Kerstjens, H. A. M. (2002) · Chest · doi:10.1378/chest.121.2.597 · Cited by 95
Current Dyspnea Among Long-Term Survivors of Early-Stage Non-small Cell Lung Cancer
Feinstein, M. B., Krebs, P., Coups, E. J., Park, B. J., Steingart, R. M., Burkhalter, J., Logue, A., & Ostroff, J. S. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181df61c8 · Cited by 56
Tsagaraki, V., Amfilochiou, A., & Markantonis, S. L. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00849.x · Cited by 24
Metadata
- Authors
- Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., & Anderson, W. H.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 115
- Issue
- 4
- Pages
- 957-965
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2088022718
- Cited by
- 520
- References
- 22
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.